Overview
Prior to joining the Mid-Atlantic Epilepsy and Sleep Center, Dr. Jonathan Ross was Director of The New England Epilepsy Institute, a division of New England Neurological Associates (NENA) in Lawrence, Massachusetts. He also served as head of the Neurology division at NENA. After graduating medical school in 1991, Dr. Ross completed postgraduate training at Harvard Medical School and Boston University School of Medicine, and also served as Teaching Fellow at Harvard and Boston University. Dr. Ross is an active member of the American Epilepsy Society, American Clinical Neurophysiology Society, Massachusetts Medical Society, and the American Academy of Neurology.
Dr. Ross is rated as an Experienced provider by MediFind in the treatment of Glioblastoma. His top areas of expertise are Seizures, Memory Loss, Autosomal Dominant Partial Epilepsy with Auditory Features, and Benign Rolandic Epilepsy.
His clinical research consists of co-authoring 49 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Suite 610, Bethesda, MD 20817
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins University
John Laterra is a Neurologist in Baltimore, Maryland. Dr. Laterra is rated as an Elite provider by MediFind in the treatment of Glioblastoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Laterra is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as a Distinguished provider by MediFind in the treatment of Glioblastoma. Her top areas of expertise are Glioma, Brain Tumor, Astrocytoma, and Glioblastoma.
Johns Hopkins Outpatient Center
Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Elite provider by MediFind in the treatment of Glioblastoma. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Autosomal Dominant Partial Epilepsy with Auditory Features
- Benign Rolandic EpilepsyDr. Ross isDistinguished. Learn about Benign Rolandic Epilepsy.
- Memory LossDr. Ross isDistinguished. Learn about Memory Loss.
- Partial Familial EpilepsyDr. Ross isDistinguished. Learn about Partial Familial Epilepsy.
- Partial SeizureDr. Ross isDistinguished. Learn about Partial Seizure.
- SeizuresDr. Ross isDistinguished. Learn about Seizures.
- Advanced
- Anti-NMDA Receptor Encephalitis
- Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
- Chronic PolyradiculoneuritisDr. Ross isAdvanced. Learn about Chronic Polyradiculoneuritis.
- Cluster HeadacheDr. Ross isAdvanced. Learn about Cluster Headache.
- Dravet SyndromeDr. Ross isAdvanced. Learn about Dravet Syndrome.
- EncephalitisDr. Ross isAdvanced. Learn about Encephalitis.
- Experienced
- Acute Cerebellar AtaxiaDr. Ross isExperienced. Learn about Acute Cerebellar Ataxia.
- Acute Flaccid Myelitis (AFM)Dr. Ross isExperienced. Learn about Acute Flaccid Myelitis (AFM).
- Alcoholic NeuropathyDr. Ross isExperienced. Learn about Alcoholic Neuropathy.
- Alzheimer's DiseaseDr. Ross isExperienced. Learn about Alzheimer's Disease.
- ApoplexyDr. Ross isExperienced. Learn about Apoplexy.
- Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency